Multiple Effects of SGLT2 Inhibitors.
作者信息
Nagasu Hajime
机构信息
Department of Nephrology and Hypertension, Kawasaki Medical School, Okayama, Japan.
出版信息
JMA J. 2024 Oct 15;7(4):580-581. doi: 10.31662/jmaj.2024-0229. Epub 2024 Sep 20.
Abstract
摘要
相似文献
1
Multiple Effects of SGLT2 Inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的多重效应
JMA J. 2024 Oct 15;7(4):580-581. doi: 10.31662/jmaj.2024-0229. Epub 2024 Sep 20.
2
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病患者高钾血症风险：来自随机对照试验的个体参与者数据的荟萃分析
Circulation. 2022 May 10;145(19):1460-1470. doi: 10.1161/CIRCULATIONAHA.121.057736. Epub 2022 Apr 8.
3
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和醛固酮拮抗剂联合肾素-血管紧张素系统拮抗剂对 2 型糖尿病合并慢性肾脏病患者主要肾脏不良结局的影响：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
4
Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在糖尿病合并慢性肾脏病（CKD）患者中的疗效和安全性：一项随机对照试验的荟萃分析
Cureus. 2022 Nov 26;14(11):e31898. doi: 10.7759/cureus.31898. eCollection 2022 Nov.
5
Investigation of cardiorenal outcomes and incidence of genitourinary tract infection after combined SGLT2 inhibitor and ACEI/ARB use in patients with chronic kidney disease stages 3-5: A real-world retrospective cohort study in Taiwan.在台湾的一项真实世界回顾性队列研究中，调查了慢性肾脏病 3-5 期患者联合使用 SGLT2 抑制剂和 ACEI/ARB 后的心肾结局和泌尿生殖道感染发生率。
Int J Med Sci. 2024 Aug 12;21(11):2109-2118. doi: 10.7150/ijms.96969. eCollection 2024.
6
Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.新型糖尿病肾病治疗药物与高钾血症风险：临床试验证据回顾。
Am J Kidney Dis. 2023 Dec;82(6):737-742. doi: 10.1053/j.ajkd.2023.04.015. Epub 2023 Jul 29.
7
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.SGLT2 抑制剂对肾脏的保护作用：在急性和慢性肾脏病中的作用。
Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.
8
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.恩格列净可能成为预防急性肾损伤的新方法。
Kidney Blood Press Res. 2019;44(2):149-157. doi: 10.1159/000498963. Epub 2019 Apr 2.
9
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.糖尿病对钠-葡萄糖共转运蛋白 2 抑制剂肾脏结局影响的荟萃分析：大型安慰剂对照试验的协作荟萃分析。
Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6.
10
Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.使用 SGLT2 抑制剂与其他降血糖药物的 2 型糖尿病患者的急性肾损伤事件：一项回顾性队列研究。
Am J Kidney Dis. 2020 Oct;76(4):471-479.e1. doi: 10.1053/j.ajkd.2020.03.019. Epub 2020 May 25.
本文引用的文献
1
Toward a Broader Conceptualization of Disparities and Solutions.迈向对差异及解决方案更广泛的概念化理解。
Circulation. 2022 Jul 19;146(3):145-146. doi: 10.1161/CIRCULATIONAHA.122.061209. Epub 2022 Jul 18.
2
SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.SGLT2 抑制剂与老年 2 型糖尿病患者急性肾损伤风险。
Am J Kidney Dis. 2022 Jun;79(6):858-867.e1. doi: 10.1053/j.ajkd.2021.09.015. Epub 2021 Nov 8.
3
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.卡格列净对 2 型糖尿病合并慢性肾脏病患者贫血的影响：来自 CREDENCE 试验的事后分析。
Lancet Diabetes Endocrinol. 2020 Nov;8(11):903-914. doi: 10.1016/S2213-8587(20)30300-4.
4
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.评估 2 型糖尿病患者使用钠-葡萄糖共转运蛋白 2 抑制剂的痛风风险：一项基于人群的队列研究。
Ann Intern Med. 2020 Feb 4;172(3):186-194. doi: 10.7326/M19-2610. Epub 2020 Jan 14.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
Zotero 插件